| scholarly article | Q13442814 |
| P50 | author | Marcela F. Pasetti | Q56380831 |
| Karen L Kotloff | Q63214788 | ||
| P2093 | author name string | William C Blackwelder | |
| Amanda D Buskirk | |||
| Shannon J Heine | |||
| Rezwanul Wahid | |||
| Avital A Shimanovich | |||
| P2860 | cites work | Global burden of Shigella infections: implications for vaccine development and implementation of control strategies | Q33749510 |
| Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity | Q33825722 | ||
| A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion | Q34192675 | ||
| Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study | Q34345075 | ||
| Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells | Q35229917 | ||
| Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis | Q35272921 | ||
| Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides | Q35335585 | ||
| Broadly protective Shigella vaccine based on type III secretion apparatus proteins | Q35805439 | ||
| Aetiology-Specific Estimates of the Global and Regional Incidence and Mortality of Diarrhoeal Diseases Commonly Transmitted through Food | Q35859832 | ||
| Human immunity to the meningococcus. I. The role of humoral antibodies | Q36269707 | ||
| Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a. | Q36920244 | ||
| Immune response against lipopolysaccharide and invasion plasmid-coded antigens of shigellae in Vietnamese and Swedish dysenteric patients. | Q37064863 | ||
| Progress and pitfalls in Shigella vaccine research | Q37105553 | ||
| Monoclonal Antibodies to Shigella Lipopolysaccharide Are Useful for Vaccine Production. | Q37163698 | ||
| Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections | Q37167794 | ||
| Role of antilipopolysaccharide antibodies in serum bactericidal activity against Salmonella enterica serovar Typhimurium in healthy adults and children in the United States | Q37252348 | ||
| Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine. | Q37335984 | ||
| Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study. | Q37477196 | ||
| Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source | Q37531323 | ||
| Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes | Q37720658 | ||
| Correlates of protection induced by vaccination | Q37750121 | ||
| Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. | Q39146446 | ||
| Differential host immune responses to epidemic and endemic strains of Shigella dysenteriae type I. | Q39408427 | ||
| Adaptive immune response to Shigella flexneri 2a cydC in immunocompetent mice and mice lacking immunoglobulin A. | Q39510614 | ||
| Thymic independence of adaptive immunity to the intracellular pathogen Shigella flexneri serotype 2a | Q39511268 | ||
| Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. | Q40267400 | ||
| Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum | Q40538332 | ||
| Characteristics of Shigella sonnei infection of volunteers: signs, symptoms, immune responses, changes in selected cytokines and acute-phase substances. | Q40683413 | ||
| Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2 | Q40687041 | ||
| Laboratory correlates of protection against Haemophilus influenzae type b disease. Importance of assessment of antibody avidity and immunologic memory | Q46136264 | ||
| Phagocytic and bactericidal properties of macrophages of mice immunized with outer membrane proteins (OMP) of Shigella | Q50198940 | ||
| Role of bacterial and host factors in the pathogenesis of Shigella septicemia. | Q54324435 | ||
| Effects of zinc supplementation as adjunct therapy on the systemic immune responses in shigellosis | Q57937885 | ||
| Delayed and reduced adaptive humoral immune responses in children with shigellosis compared with in adults | Q57939911 | ||
| Pneumococcal conjugate vaccination: correlates of protection | Q63392515 | ||
| Antibody-dependent cell-mediated antibacterial activity: K lymphocytes, monocytes, and granulocytes are effective against shigella | Q67235888 | ||
| Natural immunity to shigellosis in two groups with different previous risks of exposure to Shigella is only partly expressed by serum antibodies to lipopolysaccharide | Q68080096 | ||
| Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population | Q68134308 | ||
| Serum antibody responses against shigella lipopolysaccharides and invasion plasmid-coded antigens in shigella infected Swedish patients | Q72715742 | ||
| Characterization and quantitative analysis of serum IgG class and subclass response to Shigella sonnei and Shigella flexneri 2a lipopolysaccharide following natural Shigella infection | Q73292613 | ||
| Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media | Q81445405 | ||
| P433 | issue | 2 | |
| P921 | main subject | antibody | Q79460 |
| shigellosis | Q327298 | ||
| P577 | publication date | 2016-12-07 | |
| P1433 | published in | Clinical and Vaccine Immunology | Q5133811 |
| P1476 | title | Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study | |
| P478 | volume | 24 |
| Q91760327 | A Combined YopB and LcrV Subunit Vaccine Elicits Protective Immunity against Yersinia Infection in Adult and Infant Mice |
| Q57929967 | A Novel Proteome Microarray Discriminates Targets of Human Antibody Reactivity following Oral Vaccination and Experimental Challenge |
| Q92801042 | Characterization and immunogenicity of a Shigella flexneri 2a O-antigen bioconjugate vaccine candidate |
| Q90300290 | Complement in malaria immunity and vaccines |
| Q91801457 | Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies |
| Q47103928 | Development and Qualification of an Opsonophagocytic Killing Assay To Assess Immunogenicity of a Bioconjugated Escherichia coli Vaccine |
| Q55333715 | Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput Shigella Serum Bactericidal Assay. |
| Q56378326 | Experimental infection of human volunteers |
| Q40192692 | Human immune responses against Shigella and enterotoxigenic E. coli: Current advances and the path forward |
| Q99616552 | Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G |
| Q47578477 | In silico design of a novel chimeric shigella IpaB fused to C terminal of clostridium perfringens enterotoxin as a vaccine candidate. |
| Q57927103 | Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990-2016 |
| Q91705205 | Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model |
| Q102056730 | Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study |
| Q47701060 | Salmonella Typhi Bactericidal Antibodies Reduce Disease Severity but Do Not Protect against Typhoid Fever in a Controlled Human Infection Model |
| Q91881906 | Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis |
| Q56383780 | Shigellosis |
| Q91449694 | Updates on immunologic correlates of vaccine-induced protection |
Search more.